519 related articles for article (PubMed ID: 26342674)
1. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
Tanis E; Julié C; Emile JF; Mauer M; Nordlinger B; Aust D; Roth A; Lutz MP; Gruenberger T; Wrba F; Sorbye H; Bechstein W; Schlag P; Fisseler A; Ruers T
Eur J Cancer; 2015 Nov; 51(17):2708-17. PubMed ID: 26342674
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).
Sorbye H; Mauer M; Gruenberger T; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Collette L; Van Cutsem E; Scheithauer W; Lutz MP; Nordlinger B; ; ; ; ;
Ann Surg; 2012 Mar; 255(3):534-9. PubMed ID: 22314329
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G
Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458
[TBL] [Abstract][Full Text] [Related]
4. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
5. Multicentre study of perioperative
Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
[TBL] [Abstract][Full Text] [Related]
6. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
8. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
Beppu T; Hayashi N; Masuda T; Komori H; Horino K; Hayashi H; Okabe H; Baba Y; Kinoshita K; Akira C; Watanebe M; Takamori H; Baba H
Anticancer Res; 2010 Mar; 30(3):1015-20. PubMed ID: 20393029
[TBL] [Abstract][Full Text] [Related]
9. Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.
Ayez N; van der Stok EP; de Wilt H; Radema SA; van Hillegersberg R; Roumen RM; Vreugdenhil G; Tanis PJ; Punt CJ; Dejong CH; Jansen RL; Verheul HM; de Jong KP; Hospers GA; Klaase JM; Legdeur MC; van Meerten E; Eskens FA; van der Meer N; van der Holt B; Verhoef C; Grünhagen DJ
BMC Cancer; 2015 Mar; 15():180. PubMed ID: 25884448
[TBL] [Abstract][Full Text] [Related]
10. [Specific treatment situations in metastatic colorectal cancer].
Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
[TBL] [Abstract][Full Text] [Related]
13. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of colorectal cancer liver metastases: the immune/inflammatory infiltrate.
Giuşcă SE; Zugun FE; Târcoveanu E; Carasevici E; Amălinei C; Căruntu ID
Rom J Morphol Embryol; 2010; 51(1):73-9. PubMed ID: 20191123
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
[TBL] [Abstract][Full Text] [Related]
16. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C
Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Collette L; Praet M; Bethe U; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
Lancet; 2008 Mar; 371(9617):1007-16. PubMed ID: 18358928
[TBL] [Abstract][Full Text] [Related]
18. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.
Tanis E; Nordlinger B; Mauer M; Sorbye H; van Coevorden F; Gruenberger T; Schlag PM; Punt CJ; Ledermann J; Ruers TJ
Eur J Cancer; 2014 Mar; 50(5):912-9. PubMed ID: 24411080
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Seki H; Ozaki T; Shiina M
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
Mazzaferro V; Coppa J; Carrabba MG; Rivoltini L; Schiavo M; Regalia E; Mariani L; Camerini T; Marchianò A; Andreola S; Camerini R; Corsi M; Lewis JJ; Srivastava PK; Parmiani G
Clin Cancer Res; 2003 Aug; 9(9):3235-45. PubMed ID: 12960108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
